Article

Severity determines intraoperative floppy iris syndrome management approach

A cataract surgeon who first identified intraoperative floppy iris syndrome (IFIS) and its association with tamsulosin describes several approaches to managing the surgical complication. The approach a surgeon uses will depend on the severity of IFIS, he says.

Key Points

Dr. Chang, clinical professor of ophthalmology at the University of California, San Francisco, and in private practice in Los Altos, CA, reviewed different strategies including the use of a viscoadaptive ophthalmic viscosurgical device (OVD), intracameral epinephrine, iris retractors, and pupil expansion devices.

"When considering the management of IFIS, we must recognize that there is a wide range of severity among different patients taking tamsulosin and other alpha blockers," he said. "This means that a technique that works beautifully on one patient may not work on the next, which is why it is helpful to be adept at multiple strategies that can be used individually or in combination."

He recounted a multicenter prospective study that included 167 eyes of patients taking tamsulosin and undergoing cataract surgery. In that study, nine out of 10 eyes had IFIS of at least mild severity, and three out of four eyes had moderate to severe IFIS.

Management strategies

The first approach that Dr. Chang described, use of a highly retentive and viscoadaptive OVD, such as 2.3% sodium hyaluronate (Healon 5, Advanced Medical Optics), provides expanded pupillary dilation in patients with moderate-sized pupils, as he demonstrated in a video of a mild case of IFIS. For this strategy to be successful, one must use lower aspiration flow and vacuum settings on phacoemulsification equipment and be reasonably experienced with using this OVD, he said.

"As more [OVD] exits the eye, the floppy iris will constrict, requiring additional replenishment," Dr. Chang said. "This technique works best with reasonably large pupils and with softer nuclei, where you do not need high vacuum to optimize holding power," he added.

Dr. Chang also presented a video case of a patient who had stopped taking tamsulosin 18 months previously. After capsulorrhexis was performed and the phaco tip was inserted, the iris immediately began to billow and prolapsed to the phaco incision. After intracameral epinephrine 1:4000 (mixing 0.2 ml of 1:1000 bisulfite-free epinephrine with 0.6 ml of balanced salt solution in a 3-ml syringe) was injected, the pupil quickly dilated wider. Just as impressively, he said, the iris became more rigid, without any tendency for billowing or prolapse, and the rest of the case proceeded without any difficulty.

"This is a wonderful rescue technique, because it is more difficult to safely place iris retractors following the capsulorrhexis and hydrodissection," Dr. Chang stated. "Intracameral epinephrine is well tolerated, and for patients taking alpha blockers, there is no harm in trying it intraoperatively. While it might not always dilate the pupil further, it will at least increase iris rigidity in many cases. You can always combine [the 2.3% sodium hyaluronate OVD] with epinephrine to widen the pupil further for the capsulorrhexis step."

Patients taking tamsulosin who have pupils that dilate very poorly usually will have severe IFIS, according to Dr. Chang. "In these cases, I go straight to mechanical devices, such as iris retractors," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.